Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

计划入组 180 人 · 首次发布于 2021 年 11 月 24 日

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

计划入组 54 人 · 首次发布于 2026 年 8 月 25 日

A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

计划入组 100 人 · 首次发布于 2024 年 12 月 16 日

ALK-202

ALK-201

ALK-101

ALK-ABELLO, INC.

United States

ALK-Abelló A/S

Denmark

ALK-ABELLO A/S

Denmark

Lorlatinib Shows Impressive 5-Year PFS Results in ALK-Positive Advanced NSCLC

ALNEO Trial Demonstrates Promising Perioperative Alectinib Activity in Stage III ALK-Positive NSCLC

Alectinib Plus Bevacizumab Shows Promising Results in First-Line Treatment of ALK-Positive NSCLC